With the global market for anti-obesity drugs projected to hit $95 billion by 2030, it’s no surprise that compounded semaglutide is gaining traction as a cheaper, more accessible option. But for all its appeal, this route comes with real risks: regulatory uncertainty, legal exposure, and major insurance hurdles.
This lawsuit may look like a business dispute on the surface. But underneath, it’s about something much more important: the right of patients to receive personalized, affordable care.
Meevo offers an all-in-one solution for managing salon and spa employees. From scheduling and time tracking to payroll and promotions, Meevo streamlines operations and supports growth.
Novo Nordisk is ending its partnership with Hims & Hers due to concerns over its practices related to compounded GLP-1s.
Compounded GLP-1s have become more widespread, but are they safe? Some argue that compounding is nothing new, while others believe these drugs are dangerous for patients.